Compare iShares MSCI Japan ETF (EWJ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Novartis AG — how do they compare? iShares MSCI Japan ETF trades at $97.55 (market cap $23.87B), while Novartis AG trades at $142.98 (market cap $268.57B). The key difference: Novartis AG is far larger — about 11.3× iShares MSCI Japan ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Novartis AG for 82 Days on average.
| EWJ | NVS | |
|---|---|---|
Market Cap | $23.87B | $268.57B |
Volume | 5,412,820 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $168.62 |
52-Week Low | $78.36 | $121.80 |
Typical Hold Time | 56 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $98.32, down 1.01% on the day amid broader Asian market pressures. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. Recent news highlights Japan's monetary policy shifts with BOJ rate hikes and yen volatility creating both opportunities and challenges for Japanese equities. The ETF has demonstrated strong performance in 2026, outperforming the S&P 500 with gains exceeding 20% according to Zacks Investment Research (September 30, 2026).
The outlook for EWJ remains constructive given Japan's economic reforms and AI sector growth, though rising bond yields and currency fluctuations present near-term headwinds. Institutional interest appears strong as Japan's market rotation toward technology and AI plays supports continued ETF inflows. Key risks include BOJ policy uncertainty and global interest rate dynamics that could pressure Japanese equities.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
